SML3119
TPI-1
≥98% (HPLC), SHP-1 catalytic domain inhibitor, powder
别名:
2-(2,5-Dichloro-phenyl)-[1,4]benzoquinone; 2-(2?,5?-Dichlorophenyl)-1,4-benzoquinone, 2-(2,5-Dichlorophenyl)-2,5-cyclohexadiene-1,4-dione, TPI 1, TPI-1, TPI1
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C12H6Cl2O2
化学文摘社编号:
分子量:
253.08
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
产品名称
SHP1 Inhibitor, TPI-1, ≥98% (HPLC)
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C1C=CC(C(C2=C(C=CC(Cl)=C2)Cl)=C1)=O
InChI
1S/C12H6Cl2O2/c13-7-1-3-11(14)9(5-7)10-6-8(15)2-4-12(10)16/h1-6H
InChI key
ZKHFYORNAYYOTM-UHFFFAOYSA-N
Biochem/physiol Actions
TPI-1 is an orally bioavailable, noncytotoxic benzoquinone compound that acts as a potent irreversible inhibitor of SHP-1 (Src homology region 2 domain-containing phosphatase 1) catalytic domain (IC50 ~ 40 nM or 0.01 μg/ml) with selectivity over SHP-2 (IC50 ~ 0.1 μg/ml), MKP1 (IC50 > 1 μg/ml) and CD45. TPI-1 potently induces mouse and human primary IFN-g+ cells both in vitro and in vivo. Effectively inhibits B16 melanoma tumors in mice (1 or 3 mg/kg, s.c., daily) and prolong the survival. TPI-1 is shown to be 50-fold more effective than sodium stibogluconate in cell-based assays and may non-specifically react with cysteine residues.
orally bioavailable, noncytotoxic benzoquinone compound that acts as a potent and selective irreversible inhibitor of SHP-1 catalytic domain
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable